Erasca (ERAS) Shares Outstanding (Weighted Average) (2020 - 2026)
Erasca posted quarterly Shares Outstanding (Weighted Average) of $304.3 million for Q1 2026, up 7.43% year-on-year from $283.3 million in Q1 2025, and up 7.33% on a QoQ basis from $283.5 million in Q4 2025.
Erasca (ERAS) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $304.3 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 7.43% year-over-year to $304.3 million; the trailing twelve-month figure through Mar 2026 stood at $304.3 million (up 7.43% YoY), and the FY2025 full-year result was $283.5 million, up 21.26% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $304.3 million, up from $283.5 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $304.3 million in Q1 2026 and bottomed at $119.5 million in Q1 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $151.2 million (2024), against an average of $196.5 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) soared 437.44%; it then advanced 1.11% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $122.0 million in 2022, then rose by 23.08% to $150.2 million in 2023, then soared by 55.69% to $233.8 million in 2024, then advanced by 21.26% to $283.5 million in 2025, then rose by 7.33% to $304.3 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $304.3 million (Q1 2026), $283.5 million (Q4 2025), and $283.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 304.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304.32 Mn |
| Dec 31, 2025 | 283.53 Mn |
| Sep 30, 2025 | 283.43 Mn |
| Jun 30, 2025 | 283.31 Mn |
| Mar 31, 2025 | 283.26 Mn |
| Dec 31, 2024 | 233.82 Mn |
| Sep 30, 2024 | 217.36 Mn |
| Jun 30, 2024 | 217.81 Mn |
| Mar 31, 2024 | 151.16 Mn |
| Dec 31, 2023 | 150.18 Mn |
| Sep 30, 2023 | 150.45 Mn |
| Jun 30, 2023 | 150.04 Mn |
| Mar 31, 2023 | 149.50 Mn |
| Dec 31, 2022 | 122.02 Mn |
| Sep 30, 2022 | 120.80 Mn |
| Jun 30, 2022 | 120.19 Mn |
| Mar 31, 2022 | 119.49 Mn |
| Dec 31, 2021 | 66.29 Mn |
| Sep 30, 2021 | 48.58 Mn |
| Jun 30, 2021 | 22.89 Mn |
| Mar 31, 2021 | 22.23 Mn |
| Dec 31, 2020 | 21.04 Mn |
| Sep 30, 2020 | 21.08 Mn |
| Jun 30, 2020 | 20.73 Mn |